Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03776630 | Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors(GYNO-MIR) | active not recruiting | N/A | 363 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07096583 | An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Anhui Provincial Cancer HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05953883 | Proteogenomic Signatures Analysis In Ovarian Cancer(PROGENITOR) | active not recruiting | N/A | 24 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05591131 | Genetic Testing in African Americans(GTM-I) | active not recruiting | N/A | 21 | Augusta UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05857397 | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America(CONOR) | active not recruiting | — | 64 | Latin American Cooperative Oncology GroupOTHER | 2 | Feb 12, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation(RAMP 201) | active not recruiting | Phase 2 | 225 | Verastem, Inc.INDUSTRY | 7 | Jan 29, 2025 | clinicaltrials |
| NCT02811224 | Ovarian Cancer Hemoscope Trial | active not recruiting | — | 50 | Scripps Translational Science InstituteOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT04507841 | Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 67 | Tongji HospitalOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02321228 | Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers(TUBA) | active not recruiting | N/A | 510 | University Medical Center NijmegenOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Mupet) | active not recruiting | — | 150 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT05652283 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 37 | Bai-Rong XiaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 71 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06497270 | A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial(DISC-OVARY) | active not recruiting | N/A | 3 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03268876 | The INFLUENCE of Cytoreduction on PRO in EOC(INFLUENCE) | active not recruiting | — | 70 | Haukeland University HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04807166 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 56 | Wenjun ChengOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483425 | A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer | active not recruiting | — | 2,000 | Tongji HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2025source: clinicaltrials